PMID- 16888906
OWN - NLM
STAT- MEDLINE
DCOM- 20060912
LR  - 20081121
IS  - 0070-4113 (Print)
IS  - 0070-4113 (Linking)
VI  - 87
DP  - 2003
TI  - [Molecular cytopathology of lung cancer--prevalence of genetic alterations and 
      their role in the development of molecular biomarkers].
PG  - 142-9
AB  - Carcinogenesis of lung cancer proceeds via a complex process that involves 
      multiple genetic abnormalities, which do not necessarily have a linear 
      progression. Genetic alterations include aneuploidy, deletions and amplifications 
      of chromosomal regions, loss of heterozygosity (LOH), microsatellite alterations, 
      point mutations and aberrant promoter methylation. There is considerable effort 
      to use these genetic alterations as molecular biomarkers for early cancer 
      diagnosis applying different approaches. An ideal tumor marker should be highly 
      sensitive, tumor specific, easily to handle and non-cost intensive. While 
      previous studies used screening for mutations, LOH and microsatellite 
      alterations, more recent strategies concentrate on multicolor fluorescence in 
      situ hybridization (FISH) and aberrant promoter methylation. Since in general the 
      genetic alterations are prone to be more extensive in tumor cells as compared to 
      non-tumor cells, methods that provide quantitative data (e.g., methylation 
      specific real-time PCR) are likely to improve specificity. Consequently, 
      molecular biomarkers could constribute to a more accurate risk assessment in 
      carcinogen exposed individuals and early molecular cytologic diagnosis of 
      precancerous lesions and cancers of the lung.
FAU - Grote, H J
AU  - Grote HJ
AD  - Institut fur Cytopathologie, Heinrich-Heine-Universitat, Dusseldorf. 
      grote@med.uni-duesseldorf.de
FAU - Schmiemann, V
AU  - Schmiemann V
FAU - Bocking, A
AU  - Bocking A
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Molekulare Zytopathologie bosartiger Lungentumoren--Pravalenz der genetischen 
      Alterationen und ihre Bedeutung fur die Entwicklung molekularer Biomarker.
PL  - Germany
TA  - Verh Dtsch Ges Pathol
JT  - Verhandlungen der Deutschen Gesellschaft fur Pathologie
JID - 7503704
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Allelic Imbalance
MH  - DNA Methylation
MH  - DNA, Neoplasm
MH  - Genetic Markers
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Loss of Heterozygosity
MH  - Lung Neoplasms/*genetics/*pathology
MH  - Microsatellite Repeats/genetics
MH  - *Mutation
MH  - Point Mutation
MH  - Promoter Regions, Genetic
RF  - 47
EDAT- 2006/08/08 09:00
MHDA- 2006/09/13 09:00
CRDT- 2006/08/08 09:00
PHST- 2006/08/08 09:00 [pubmed]
PHST- 2006/09/13 09:00 [medline]
PHST- 2006/08/08 09:00 [entrez]
PST - ppublish
SO  - Verh Dtsch Ges Pathol. 2003;87:142-9.